Kanika Suri
Drug Product & Device Development, CMC Scientist Scientist
Kanika Suri, PhD, is passionate about developing innovative, effective, and patient-friendly therapies for debilitating conditions. At Takeda, she leads CMC development for pipeline drug products across proteins, peptides, nucleic acids, and synthetic small molecules, tackling formulation and delivery challenges for oral, topical, and parenteral routes. With deep R&D experience, Dr. Suri translates scientific insight into pragmatic, patient-centric, phase-appropriate solutions that progress smoothly through clinical trials.
Her academic work underscores a long-standing focus on drug delivery. During her PhD, she developed a novel oral delivery platform for nucleic acids, building on her Master’s research on bioactive permeation enhancers to improve macromolecule absorption. A champion of innovation and an advocate for Women in STEM, Dr. Suri pairs scientific rigor with purpose-driven leadership to help advance the next generation of therapies.
Seminars
- Compare lipid and polymeric nanoparticle platforms with a specific focus on extra hepatic payload delivery
- Differences in biodistribution, cellular uptake, endosomal escape, payload compatibility, repeat dosing, and translational readiness
- Highlight why extrahepatic delivery remains challenging for lipid nanoparticles and where polymeric systems may offer advantages, as well as the trade-offs involved in moving beyond clinically validated lipid platforms
- Where do LNPs begin to show limitations for extrahepatic delivery and which emerging delivery vehicles offer the most realistic advantages?
- How do alternative delivery platforms compare in terms of manufacturability, scalability, safety, and regulatory readiness when moving towards the clinic?
- Which delivery challenges, from immunogenicity to targeting specificity, are best addressed by exploring non-LNP platforms, and where do LNPs remain the most practical solution?
